Dr. April Rose on BEAVER Trial & New BRAF Cancer Therapies | ASCO 2024 скачать в хорошем качестве

Dr. April Rose on BEAVER Trial & New BRAF Cancer Therapies | ASCO 2024

In this episode of OncoDaily, Dr. April Rose from the Jewish General Hospital shares results from the phase two BEAVER trial presented at ASCO. The trial targets advanced cancers driven by non-V600E BRAF mutations, which currently lack effective treatments. Dr. Rose discusses the combination of Binimetinib (MEK inhibitor) and Encorafenib (BRAF inhibitor), showing a 13% response rate among 23 patients, with the best results in melanoma. She also highlights promising new triple therapy strategies with SHIP2 and CDK4/6 inhibitors, which could improve outcomes for these cancers. ‪@thejghfoundation‬ Abstract:- https://doi.org/10.1200/JCO.2024.42.1... #CancerResearch #BEAVERTrial #BRAFMutations #NonV600EBRAF #MelanomaTreatment #AdvancedCancer #Binimetinib #Encorafenib #MEKinhibitors #BRAFinhibitors #TripleTherapy #SHIP2Inhibitors #CDK46Inhibitors #TargetedTherapies #OncologyUpdates #CancerTrials #ASCO2024 #ClinicalTrials #CancerBreakthroughs #OncoDaily #InnovativeCancerTreatments #OncologyResearch #TumorMutations #CancerTherapies #CancerCare SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”